SwePub
Sök i LIBRIS databas

  Extended search

(L773:1552 5279 OR L773:1552 5260) lar1:(lu) pers:(Hansson Oskar)
 

Search: (L773:1552 5279 OR L773:1552 5260) lar1:(lu) pers:(Hansson Oskar) > (2010-2014) > An enzyme activity ...

  • Andreasson, U. (author)

An enzyme activity as a potential biomarker for Alzheimer's disease.

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • 2010-07
  • Wiley,2010

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:47f24030-2073-4243-b1e3-9e0ea1a6e9f0
  • https://lup.lub.lu.se/record/47f24030-2073-4243-b1e3-9e0ea1a6e9f0URI
  • https://doi.org/10.1016/j.jalz.2010.05.1662DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:kon swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background: Six different N-terminal amyloid precursor protein (APP) fragments, with molecular weight ∼12 kDa, have previously been identified in human cerebrospinal fluid (CSF). In a pilot study, both the sum of their concentrations, measured by western blot, and the relative abundance pattern, measured by mass spectrometry, were different in Alzheimer's disease (AD) patients compared to healthy controls. To test if these differences were also reflected in protease activities that possibly give rise to the ∼12 kDa fragments an enzymatic assay was developed and the activity in CSF was investigated for its potential as a biomarker for AD. Methods: The substrate in the protease activity assay was a custom made fluorochrome/quencher labeled peptide that covers the cleavage sites in APP (APP118-APP127) corresponding to the C-termini of the six ∼12 kDa APP fragments. The activity was measured in CSF from 55 AD patients and 17 controls. Results: There was a significant increase in the protease activity in CSF from AD patients compared to the controls (p = 0.001). This is in line with previous results which indicate that the sum of the ∼12 kDa fragments are elevated in AD. Results from inhibition studies strongly suggests that the enzyme responsible for the cleavage of the substrate is an aspartic protease since a sub nM IC50 value was recorded for Pepstatin A while no inhibition was observed for the cysteine protease specific inhibitor E64 at concentrations up to100 nM. Conclusions: There exists an enzymatic activity in CSF capable of cleaving a peptide substrate that spans a portion, close to the N-terminal, of APP. In a pilot study the activity is increased in AD patients compared to controls suggesting that it can be used as a biomarker.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bjerke, M. (author)
  • Gobom, J. (author)
  • Hansson, OskarLund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups(Swepub:lu)mphy-ohn (author)
  • Johansson, PerSkaraborg Hospital(Swepub:lu)med-pjh (author)
  • Svensson, J. (author)
  • Zetterberg, H. (author)
  • Blennow, K. (author)
  • Klinisk minnesforskningForskargrupper vid Lunds universitet (creator_code:org_t)

Related titles

  • In:Alzheimer's & Dementia: Wiley6:4, s. 497-4981552-52791552-5260

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view